Telix Pharmaceuticals Limited (TLX) issued an update on its commercial and operational performance for the quarter ended 30 June 2025. Second quarter group revenue was approximately $204 million, up 63% year-over-year. Global Illuccix revenue was $154 million, an increase of 25% from last year. Telix confirmed its fiscal 2025 revenue guidance of $770 million to $800 million.
Telix noted that it has received a subpoena from the SEC seeking various documents and information primarily relating to the company's disclosures regarding the development of the prostate cancer therapeutic candidates. The company said it is fully cooperating with the SEC and is in the process of responding to the information request.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.